Diabetic Medicine最新文献

{"title":"Research Independence in Academia—‘The holy grail’ and beyond","authors":"Daniela Nasteska, Pia Leete","doi":"10.1111/dme.15406","DOIUrl":"10.1111/dme.15406","url":null,"abstract":"","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141731103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Footwear fit as a causal factor in diabetes-related foot ulceration: A systematic review","authors":"Petra J. Jones,&nbsp;David G. Armstrong,&nbsp;Robert Frykberg,&nbsp;Melanie Davies,&nbsp;Alex V. Rowlands","doi":"10.1111/dme.15407","DOIUrl":"10.1111/dme.15407","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Incorrectly fitting footwear (IFF) poses a risk of trauma to at-risk feet with diabetes. The aim of this systematic review was to summarise and assess the evidence that IFF is a statistically significant cause of ulceration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We searched PubMed, Scopus, Web of Science and Google Scholar for English-language peer-reviewed studies reporting the number or percentage of people with diabetes-related foot ulceration (DFU) attributed to wearing IFF and included a physical examination of the footwear worn. Two independent reviewers assessed the risk of bias using the Newcastle–Ottawa scale.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>4318 results were retrieved excluding duplicates with 45 studies shortlisted. Ten studies met the inclusion criteria with most rated as fair (<i>n</i> = 6) or good (<i>n</i> = 3). There is some evidence that DFU is significantly associated with IFF, but this is limited: only 3 of 10 included studies found a statistically significant percentage of those with DFU were wearing IFF or inappropriate footwear which included fastening, material, type or fit (15.0%–93.3%). Risk of bias in these three studies ranged from ‘fair’ to ‘poor’. IFF definitions were often unreported or heterogeneous. Only one study reported IFF-related ulcer sites: 70% were at plantar hallux/toes and 10% at plantar metatarsal heads.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>There is some evidence that IFF is a cause of DFU, but further research is needed, which defines IFF, and methodically records footwear assessment, ulcer location and physical activity. Researchers need to uncover why IFF is worn and if this is due to economic factors, a need for footwear education or other reasons.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Switching to reusable cartridge insulin pens can reduce National Health Service costs while delivering environmental benefits","authors":"Vincent Simpson,&nbsp;Angus Jones","doi":"10.1111/dme.15409","DOIUrl":"10.1111/dme.15409","url":null,"abstract":"&lt;p&gt;The climate crisis is a risk to health globally and reducing carbon emissions is a priority for the UK and other nations.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The NHS is the largest public sector contributor to England's national carbon footprint, accounting for 4% of England's total carbon footprint.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; In response, the NHS committed to achieve net zero by 2045.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Within the NHS, pharmaceuticals account for an estimated 25% of emissions.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Despite pharmaceuticals' significant contributions, no national guidelines exist to help clinicians and patients make informed, sustainable decisions.&lt;/p&gt;&lt;p&gt;7% of England's population has been diagnosed with diabetes.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Insulin is the only licenced medication for individuals with type 1 diabetes and is often needed to control glucose levels in individuals with type 2 diabetes.&lt;span&gt;&lt;sup&gt;4, 5&lt;/sup&gt;&lt;/span&gt; Most of those administering insulin use an insulin pen, either a disposable pen that is fully replaced when insulin is exhausted, or a reusable cartridge pen that can last for several years. In the UK, Novo Nordisk and Sanofi currently offer recycling of their disposable insulin pens.&lt;span&gt;&lt;sup&gt;6, 7&lt;/sup&gt;&lt;/span&gt; However, the number of disposable insulin pens returned for recycling is unclear. Current guidelines do not advise on the insulin delivery system clinicians should use. We aimed to assess the current number of disposable insulin pens prescribed in England compared to cartridge insulin (requiring a reusable cartridge pen) and compare differences in plastic waste, carbon footprint (CO&lt;sub&gt;2&lt;/sub&gt;eq) and prescribing cost to the NHS.&lt;/p&gt;&lt;p&gt;To compare the environmental impact of disposable and reusable insulin pens, we contacted all major manufacturers (Novo Nordisk, Eli Lilly and Company and Sanofi) of insulin in England for data on their products, including the quantity of plastic and life cycle assessments (LCA). Novo Nordisk provided plastic content data and LCA of their insulin products.&lt;span&gt;&lt;sup&gt;8-10&lt;/sup&gt;&lt;/span&gt; Sanofi provided data on plastic content only, therefore, carbon footprint could not be calculated. Eli Lilly and Company could not provide any data on their products, so only data on cost impacts are presented. LCA data provided by Novo Nordisk were calculated by adding the greenhouse gas contributions from the active pharmaceutical ingredient (API), device, cartridge and needle.&lt;span&gt;&lt;sup&gt;8-10&lt;/sup&gt;&lt;/span&gt; Plastic weight is presented in kilograms (kg) and LCA as CO&lt;sub&gt;2&lt;/sub&gt; equivalent (CO&lt;sub&gt;2&lt;/sub&gt;eq). To assess the cost of disposable and reusable pens to England's National Health Service (NHS) we obtained NHS indicative prices (in pound sterling, £) of insulin products from the British National Formulary (BNF).&lt;span&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;/span&gt; We used this information to calculate the cost, plastic waste and carbon footprint difference per prescription between disposable and the equivalent cartridge insulin. To","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15409","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on technologies, medicines and treatments","authors":"Simon O'Neill","doi":"10.1111/dme.15395","DOIUrl":"10.1111/dme.15395","url":null,"abstract":"<p>We know that being more active is important for preventing type 2 diabetes and managing blood glucose levels, but a recent study has looked specifically at walking and whether the speed you move can have an impact on your risk of developing type 2 diabetes.<span>¹</span></p><p>Researchers collected data from 10 prospective cohort studies undertaken in the United States, Japan and the United Kingdom. The duration of the studies was between 3 and 11 years. Walking speed was divided in to four categories—easy or casual (less than 2 mph), average or normal (2–3 mph), fairly brisk (3–4 mph) and very brisk or brisk/striding (greater than 4 mph).</p><p>People who walk at the average speed had a 15% lower risk of developing type 2 diabetes than those who walk at the easy/casual speed and those who walked at a fairly brisk pace had a 24% lower risk. Those who walked the fastest had nearly a 40% lower relative risk. They also looked at whether adjusting for total physical activity or time spent walking per day changed these findings, but walking at a faster pace still showed benefits for reducing risk, regardless of these factors.</p><p>The researchers pointed out some limitations to their study, as the different cohort studies did not all measure walking speed or diagnosis of type 2 diabetes in the same way. They also point out that participants with faster walking speed are more likely to perform more physical activity and have better cardiorespiratory fitness, greater muscle mass and better health status. But overall, they concluded that increasing the pace when you walk could be an extra boost for preventing type 2 diabetes, on top of just walking more in general.</p><p>Researchers at Texas A&amp;M University have found evidence suggesting a connection between type 2 diabetes and Alzheimer's disease. In their study, which has not yet been published in a scientific journal, the researchers investigated how these two diseases are related by conducting experiments on mice. They discovered that a specific protein in the gut, called jak3, is affected by consuming a high-fat diet. When this protein is suppressed, mice experienced inflammation starting from the intestine, spreading to the liver and the brain. These mice then displayed symptoms similar to Alzheimer's, such as memory loss.</p><p>The researchers propose that managing or avoiding type 2 diabetes could potentially reduce the risk of Alzheimer's disease. Previous studies have shown a link between diet, lifestyle and the development of both diabetes and Alzheimer's. Additionally, the researchers found that the jak3 protein is associated with a condition called leaky gut, which causes chronic inflammation and may contribute to the development of type 2 diabetes, as well as impair the brain's ability to clear toxins, leading to dementia-like symptoms.</p><p>By adopting a healthy diet and managing blood sugar levels, it might be possible to prevent or mitigate these diseases. This could i","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15395","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of exercise patterns in people with type 1 diabetes—insights from the Hedia diabetes assistant mobile app","authors":"Kenney Fehrenkamp Pedersen,&nbsp;Stig Molsted,&nbsp;Pernille Rudebeck Mogensen,&nbsp;Anne Østerskov,&nbsp;Gkikas Karagkounis,&nbsp;Peter Lommer Kristensen","doi":"10.1111/dme.15410","DOIUrl":"10.1111/dme.15410","url":null,"abstract":"","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes misconceptions, seriousness, motivation, self-efficacy and stigma: A cross-sectional comparison of eight Australian diabetes communication campaign videos","authors":"Elizabeth Holmes-Truscott,&nbsp;Jessica L. Hateley-Browne,&nbsp;Elizabeth Charalambakis,&nbsp;Adriana D. Ventura,&nbsp;Annette Ripper,&nbsp;Renza Scibilia,&nbsp;Jane Speight","doi":"10.1111/dme.15399","DOIUrl":"10.1111/dme.15399","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This study examines potential intended (attitudes, motivation and self-efficacy) and unintended (stigmatisation of diabetes) consequences of past Australian National Diabetes Week campaign videos. Further, outcomes are compared by the extent to which participants perceived their allocated video as stigmatising diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this cross-sectional, ten-arm study, participants (adults with or without diabetes; 1:2 ratio) were randomly allocated to view one of eight archival diabetes campaign videos (intervention), or either an active or passive control group. Post-exposure, study-specific scales measured diabetes Misconceptions and Seriousness, General and Diabetes Risk-Reduction Motivation and Self-efficacy, and perceptions of video Stigmatisation of diabetes. Scores were compared by condition (intervention vs. control) and by campaign Stigma (highest vs. lowest tertile score), separately by cohort (with or without diabetes).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The sample included <i>n</i> = 1023 without diabetes; and <i>n</i> = 510 with diabetes (79% type 2 diabetes). No significant differences in outcomes were observed between conditions (intervention vs. control), with one exception: a modest effect on General Self-efficacy among those without diabetes only. Those perceiving high campaign Stigma (15%), relative to low Stigma (60%), reported significantly greater diabetes Misconceptions, lower perceived Seriousness and (among those without diabetes only) lower General Motivation but higher Diabetes Risk Reduction Motivation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Though limited to a single-exposure, we found little meaningful positive influence of past diabetes campaign videos on diabetes attitudes, behavioural intentions or self-efficacy. Further, campaign videos were perceived as stigmatising by a minority—a potential harmful impact. This novel study has implications for the design, implementation and evaluation of future diabetes campaigns.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15399","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141598883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting senescence to prevent diabetic kidney disease: Exploring molecular mechanisms and potential therapeutic targets for disease management.","authors":"Paige Charlotte Alison Phillips, Mafalda de Sousa Loreto Aresta Branco, Chelsy Louise Cliff, Joanna Kate Ward, Paul Edward Squires, Claire Elizabeth Hills","doi":"10.1111/dme.15408","DOIUrl":"https://doi.org/10.1111/dme.15408","url":null,"abstract":"<p><strong>Background/aims: </strong>As a microvascular complication, diabetic kidney disease is the leading cause of chronic kidney disease and end-stage renal disease worldwide. While the underlying pathophysiology driving transition of diabetic kidney disease to renal failure is yet to be fully understood, recent studies suggest that cellular senescence is central in disease development and progression. Consequently, understanding the molecular mechanisms which initiate and drive senescence in response to the diabetic milieu is crucial in developing targeted therapies that halt progression of renal disease.</p><p><strong>Methods: </strong>To understand the mechanistic pathways underpinning cellular senescence in the context of diabetic kidney disease, we reviewed the literature using PubMed for English language articles that contained key words related to senescence, inflammation, fibrosis, senescence-associated secretory phenotype (SASP), autophagy, and diabetes.</p><p><strong>Results: </strong>Aberrant accumulation of metabolically active senescent cells is a notable event in the progression of diabetic kidney disease. Through autocrine- and paracrine-mediated mechanisms, resident senescent cells potentiate inflammation and fibrosis through increased expression and secretion of pro-inflammatory cytokines, chemoattractants, recruitment of immune cells, myofibroblast activation, and extracellular matrix remodelling. Compounds that eliminate senescent cells and/or target the SASP - including senolytic and senomorphics drugs - demonstrate promising results in reducing the senescent cell burden and associated pro-inflammatory effect.</p><p><strong>Conclusions: </strong>Here we evidence the link between senescence and diabetic kidney disease and highlight underlying molecular mechanisms and potential therapeutic targets that could be exploited to delay disease progression and improve outcomes for individuals with the disease. Trials are now required to translate their therapeutic potential to a clinical setting.</p>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141598884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A cross-sectional time series of cardiometabolic health education format preferences across sociodemographic groups","authors":"Angharad Woolley,&nbsp;Michelle Hadjiconstantinou,&nbsp;Danielle H. Bodicoat,&nbsp;Kamlesh Khunti,&nbsp;Melanie J. Davies,&nbsp;Samuel Seidu","doi":"10.1111/dme.15404","DOIUrl":"10.1111/dme.15404","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Health education is integral to cardiometabolic disease (CMD) management. This study aimed to assess whether and how education preferences have changed over time, and whether trends differ by sociodemographic characteristics (education status, age, ethnicity, and sex).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional questionnaire was deployed across five counties in the East Midlands, UK between 2017 and 2022 to adults with CMD (type 2 diabetes, cardiovascular disease or cerebrovascular disease). Respondent demographic data were collected alongside health education preferences. Statistical analyses ascertained whether demographic characteristics influenced preferences. The distribution of preferences over time was charted to identify trends.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 4301 eligible responses were collected. Face-to-face one-to-one education was preferred (first choice for 75.1% of participants) but popularity waned over the five-year period. Trends were similar amongst demographic groups. Online education showed a U-shaped trend: In 2017, 44% of respondents ranked it as acceptable, peaking at 53% in 2019, but declining again, to below base line, 43%, by 2022. This modality was more popular with participants aged younger than 65 years, but popularity in people older than 65 years increased over the study period. The popularity of printed information also declined over time across all demographic groups except those of South Asian ethnicity, for whom it remained static.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The overwhelming preference for face-to-face one-to-one health education from a doctor or nurse highlights the importance of preserving access to this modality, even in the face of current NHS pressures and trends towards digitalisation. Trends are changing, and should continue to be monitored, including between different sociodemographic groups.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15404","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of diabetes in people with advanced chronic kidney disease.","authors":"Tahseen A Chowdhury, Dorcas Mukuba, Mahalia Casabar, Conor Byrne, M Magdi Yaqoob","doi":"10.1111/dme.15402","DOIUrl":"https://doi.org/10.1111/dme.15402","url":null,"abstract":"<p><p>Diabetes is the commonest cause of end stage kidney disease globally, accounting for almost 40% of new cases requiring renal replacement therapy. Management of diabetes in people with advanced kidney disease on renal replacement therapy is challenging due to some unique aspects of assessment and treatment in this group of patients. Standard glycaemic assessment using glycated haemoglobin may not be valid in such patients due to altered red blood cell turnover or iron/erythropoietin deficiency, leading to changed red blood cell longevity. Therefore, use of continuous glucose monitoring may be beneficial to enable more focussed glycaemic assessment and improved adjustment of therapy. People with advanced kidney disease may be at higher risk of hypoglycaemia due to a number of physiological mechanisms, and in addition, therapeutic options are limited in such patients due to lack of experience or license. Insulin therapy is the basis of treatment of people with diabetes with advanced kidney disease due to many other drugs classes being contraindicated. Targets for glycaemic control should be adjusted according to co-morbidity and frailty, and continuous glucose monitoring should be used in people on dialysis to ensure low risk of hypoglycaemia. Post-transplant diabetes is common amongst people undergoing solid organ transplantation and confers a greater risk of mortality and morbidity in kidney transplant recipients. It should be actively screened for and managed in the post-transplant setting.</p>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food insecurity and diabetes management among adults of African descent: A systematic review","authors":"Cherlie Magny-Normilus,&nbsp;Francesca Luppino,&nbsp;Karen Lyons,&nbsp;Jason Luu,&nbsp;Jacquelyn Y. Taylor","doi":"10.1111/dme.15398","DOIUrl":"10.1111/dme.15398","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This systematic review explores the established causal link between food insecurity and cardiometabolic conditions among adults of African descent. Specifically, this study examined the relationship between food insecurity and the management of type 2 diabetes, highlighting the prevalence of food insecurity among individuals of African descent with type 2 diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Original English papers were meticulously searched in databases including PubMed, CINAHL, PsycINFO, Medline, Cochrane, Embase and Web of Science. The Cochrane Risk of Bias Tool for quantitative studies and COReQ for qualitative studies were employed to assess biases. Three independent reviewers meticulously evaluated and synthesized results, reaching a consensus.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 198 studies identified, 14 met the inclusion criteria for data extraction and analysis, which were conducted independently by three reviewers. The findings indicate that individuals of African descent are more likely to experience food insecurity compared to their White counterparts and are also more prone to diabetes risk factors or the presence of diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study underscores a higher prevalence of food insecurity and type 2 diabetes among adults of African descent, suggesting that ethnicity and food insecurity play significant roles in diabetes management. Future research should prioritize interventions aimed at reducing these disparities.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15398","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}